Specimen Validity Testing: Global Strategic Business Report

Global Specimen Validity Testing Market to Reach $3.9 Billion by 2030

The global market for Specimen Validity Testing estimated at US$2.6 Billion in the year 2022, is projected to reach a revised size of US$3.9 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2022-2030. Products, one of the segments analyzed in the report, is projected to record 4.6% CAGR and reach US$2.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Services segment is readjusted to a revised 6.5% CAGR for the next 8-year period.

The U.S. Market is Estimated at $756.4 Million, While China is Forecast to Grow at 4.9% CAGR

The Specimen Validity Testing market in the U.S. is estimated at US$756.4 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$683.2 Million by the year 2030 trailing a CAGR of 4.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.7% and 4.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4% CAGR.

Select Competitors (Total 42 Featured) -

• Acm Global Laboratories
• Alfa Scientific Designs, Inc.
• Clinical Reference Laboratory, Inc.
• Express Diagnostics Int'l, Inc.
• Premier Brands of America, Inc.
• Quest Diagnostics, Inc.
• Sciteck, Inc.
• Thermo Fisher Scientific, Inc.

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and Research Platform
• Complimentary updates for one year